Cargando…
A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice
BACKGROUND: Rabies is a fatal disease that is preventable when post exposure prophylaxis (PEP) is administered in a timely fashion. CpG oligodeoxynucleotides (ODNs) can trigger cells that express Toll-like receptor 9, and their immunopotentiation activity in an inactivated aluminum-adjuvanted rabies...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234694/ https://www.ncbi.nlm.nih.gov/pubmed/30424815 http://dx.doi.org/10.1186/s12985-018-1089-1 |
_version_ | 1783370751408078848 |
---|---|
author | Yu, Pengcheng Yan, Jianghong Wu, Weicheng Tao, Xiaoyan Lu, Xuexin Liu, Shuqing Zhu, Wuyang |
author_facet | Yu, Pengcheng Yan, Jianghong Wu, Weicheng Tao, Xiaoyan Lu, Xuexin Liu, Shuqing Zhu, Wuyang |
author_sort | Yu, Pengcheng |
collection | PubMed |
description | BACKGROUND: Rabies is a fatal disease that is preventable when post exposure prophylaxis (PEP) is administered in a timely fashion. CpG oligodeoxynucleotides (ODNs) can trigger cells that express Toll-like receptor 9, and their immunopotentiation activity in an inactivated aluminum-adjuvanted rabies vaccine for dogs has been identified using mouse and dog models. METHODS: A human diploid cell rabies vaccine (HDCV) of humans and a CpG ODNs with cross-immunostimulatory activity in humans and mice were used to evaluate the immunogenicity and protective efficacy of CpG ODN in a mouse model that simulates human PEP. RESULTS: HDCV combined with CpG ODN (HDCV–CpG) stimulated mice to produce rabies virus-specific neutralizing antibody (RVNA) earlier and increased the seroconversion rate. Compared with HDCV alone, either HDCV–1.25 μg CpG or HDCV–5 μg CpG increased the levels of RVNA. In particular, 5 μg CpG ODN per mouse significantly boosted the levels of RVNA compared with HDCV alone. IFN-γ producing splenocytes generated in the HDCV-5 μg CpG group were significantly increased compared to the group treated with HDCV alone. When the immunization regimen was reduced to three injections or the dose was reduced to half of the recommended HDCV combined with CpG ODN, the RVNA titers were still higher than those induced by HDCV alone. After viral challenge, 50% of mice immunized with a half-dose HDCV–CpG survived, while the survival rate of mice immunized with HDCV alone was 30%. CONCLUSIONS: The immunopotentiation activity of CpG ODNs for a commercially available human rabies vaccine was first evaluated in a mouse model on the basis of the Essen regimen. Our results suggest that the CpG ODN used in this study is a potential adjuvant to rabies vaccines for human use. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-1089-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6234694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62346942018-11-20 A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice Yu, Pengcheng Yan, Jianghong Wu, Weicheng Tao, Xiaoyan Lu, Xuexin Liu, Shuqing Zhu, Wuyang Virol J Research BACKGROUND: Rabies is a fatal disease that is preventable when post exposure prophylaxis (PEP) is administered in a timely fashion. CpG oligodeoxynucleotides (ODNs) can trigger cells that express Toll-like receptor 9, and their immunopotentiation activity in an inactivated aluminum-adjuvanted rabies vaccine for dogs has been identified using mouse and dog models. METHODS: A human diploid cell rabies vaccine (HDCV) of humans and a CpG ODNs with cross-immunostimulatory activity in humans and mice were used to evaluate the immunogenicity and protective efficacy of CpG ODN in a mouse model that simulates human PEP. RESULTS: HDCV combined with CpG ODN (HDCV–CpG) stimulated mice to produce rabies virus-specific neutralizing antibody (RVNA) earlier and increased the seroconversion rate. Compared with HDCV alone, either HDCV–1.25 μg CpG or HDCV–5 μg CpG increased the levels of RVNA. In particular, 5 μg CpG ODN per mouse significantly boosted the levels of RVNA compared with HDCV alone. IFN-γ producing splenocytes generated in the HDCV-5 μg CpG group were significantly increased compared to the group treated with HDCV alone. When the immunization regimen was reduced to three injections or the dose was reduced to half of the recommended HDCV combined with CpG ODN, the RVNA titers were still higher than those induced by HDCV alone. After viral challenge, 50% of mice immunized with a half-dose HDCV–CpG survived, while the survival rate of mice immunized with HDCV alone was 30%. CONCLUSIONS: The immunopotentiation activity of CpG ODNs for a commercially available human rabies vaccine was first evaluated in a mouse model on the basis of the Essen regimen. Our results suggest that the CpG ODN used in this study is a potential adjuvant to rabies vaccines for human use. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-1089-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-13 /pmc/articles/PMC6234694/ /pubmed/30424815 http://dx.doi.org/10.1186/s12985-018-1089-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Yu, Pengcheng Yan, Jianghong Wu, Weicheng Tao, Xiaoyan Lu, Xuexin Liu, Shuqing Zhu, Wuyang A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice |
title | A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice |
title_full | A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice |
title_fullStr | A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice |
title_full_unstemmed | A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice |
title_short | A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice |
title_sort | cpg oligodeoxynucleotide enhances the immune response to rabies vaccination in mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234694/ https://www.ncbi.nlm.nih.gov/pubmed/30424815 http://dx.doi.org/10.1186/s12985-018-1089-1 |
work_keys_str_mv | AT yupengcheng acpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT yanjianghong acpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT wuweicheng acpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT taoxiaoyan acpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT luxuexin acpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT liushuqing acpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT zhuwuyang acpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT yupengcheng cpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT yanjianghong cpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT wuweicheng cpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT taoxiaoyan cpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT luxuexin cpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT liushuqing cpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice AT zhuwuyang cpgoligodeoxynucleotideenhancestheimmuneresponsetorabiesvaccinationinmice |